Cytori Therapeutics (CYTX) Tops Q2 EPS by 2c

Cytori Therapeutics (NASDAQ: CYTX) reported Q2 EPS of ($0.19), $0.02 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.23 million.

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• KULR Technology Group (KULR) Misses Q2 EPS by 39c